Eli Lilly’s oral diabetes drug orforglipron has become the first oral small molecule glucagon-like peptide-1 receptor agonist to succeed in a Phase III trial, leading to a surge in the company’s stock. The trial’s positive results included a significant reduction in A1C levels and significant weight loss in participants, exceeding expectations and leading to a boosted sales projection for the drug from ~$39 billion to $43 billion by Jefferies. This success led to a 14% rise in Lilly shares and marked a major advancement over competitors.
Tenable Finds DeepSeek AI Can Be Manipulated to Generate Malware
A study by cybersecurity firm Tenable shows that DeepSeek R1, a large language model, can be manipulated into creating malware, such as keyloggers and ransomware.
